Engineers Gate Manager’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Engineers Gate Manager’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-32,089	Closed	-$1.19M	–	2111
2023 Q1	$1.19M	Buy	32,089 +26,774	+504%	+$1.2M	0.05%	529
2022 Q4	$241K	Sell	5,315 -7,052	-57%	-$456K	0.01%	1293
2022 Q3	$864K	Buy	+12,367	New	+$915K	0.05%	505
2022 Q2	–	Sell	-25,822	Closed	-$2.12M	–	2340
2022 Q1	$2.12M	Buy	25,822 +20,806	+415%	+$2.13M	0.08%	311
2021 Q4	$736K	Buy	5,016 +1,939	+63%	+$301K	0.03%	787
2021 Q3	$544K	Sell	3,077 -15,588	-84%	-$2.51M	0.03%	818
2021 Q2	$3.02M	Buy	18,665 +14,284	+326%	+$2.29M	0.19%	98
2021 Q1	$750K	Sell	4,381 -6,085	-58%	-$1.2M	0.04%	730
2020 Q4	$2.3M	Buy	+10,466	New	+$2.26M	0.1%	285

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Engineers Gate Manager's MRTX Position: Q2 2023 in Review

Engineers Gate Manager sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2023, closing a stake of 32,089 shares — an estimated $1.19M sold.

Engineers Gate Manager first reported a position in MRTX in Q4 2020 and held it in 9 quarters. The position peaked at $3.02M in Q2 2021. 207 funds tracked by Wall St. Rank hold MRTX as of Q2 2023.

Engineers Gate Manager reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Engineers Gate Manager sold 32,089 Mirati Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $1.19M.
Engineers Gate Manager first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2020 and held it in 9 quarters.
Engineers Gate Manager's Mirati Therapeutics, Inc. Common Stock position peaked at $3.02M in Q2 2021.
207 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Engineers Gate Manager's 13F filing for Q2 2023, filed 14 Aug 2023.